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Use of Staphylococcus aureus Phage Lysate Staphage Lysate (SPL)®  
for the Control of Recurrent Pyoderma Eczema in Dogs with Atopic Dermatitis
Suzana Evelyn Bahr Solomon1, Marconi Rodrigues de Farias2 & Claudia Turra Pimpão2
ABSTRACT
Background: Recurrent staphylococcal infections are frequent in dogs with atopic dermatitis (AD). Many factors seem 
to contribute to making bacterial pyoderma refractory to treatment. Short-term systemic antibiotic therapy is effective for 
the treatment of acute symptoms, and may, along with pulsatile therapy, contribute to the long-term control of the disease. 
However, microbial resistance has become a growing and alarming problem. The aim of this study was to evaluate whether 
the use of Staphylococcus aureus Phage Lysate Staphage Lysate (SPL)®, can minimize the symptoms of recurrent pyoderma 
and increase the interval between acute atopic manifestations in dogs.
Materials, Methods & Results: Thirteen dogs with a history of Canine Atopic Dematitis (CAD) and recurrent bacterial 
pyoderma received SPL at increasing intervals for 23 weeks. The contents of an intact pustule of each dog was collected 
and submitted to microbiological analysis. Systemic antibiotic therapy was established for the first 4-6 weeks of SPL 
protocol, based on the antibiotic sensitivity tests. The animals included in the study underwent a therapeutic protocol 
receiving shots of 0.5 mL of SPL subcutaneously (SC) twice a week for the first 12 weeks; 1.0 mL of SPL (SC) once a 
week for four weeks; 1.0 mL of SPL (SC) once every 15 days; 1.0 mL of SPL (SC) after a three-week interval from the 
last dose on week 20, until final observation at week 26, with no application. The animals underwent clinical examination 
every week and the evaluation of pruritus was used according Rybnicek et al. During the therapeutic protocol with SPL, 
a significant decline in the pruritus was observed in the treated dogs (P < 0.05). In week 1, the mean pruritus index was 
7.33 on the Rybnicek scale; in weeks 12 and 23, the mean indices were 2.41 and 1.91. An effectiveness of 83.33% for the 
control of pruritus along with regression of the lesions was observed.
Discussion: Before treatment, the selected animals presented worsening of the pruritus during the pyoderma eczema epi-
sodes (pruritic), resulting in the emergence of a vicious cycle where the pruritus induced the appearance of new lesions, 
requiring the use of antibiotics for a long period. During the therapeutic protocol with SPL, a significant decline in the 
pruritus was observed in the treated dogs. The control of pruritus associated with pyoderma eczema of the dogs in this 
study before the vaccination protocol with SPL was satisfactory when they were subjected to antibiotic therapy; however, 
after suspending therapy, the bacterial infections recurred, on average, after 2-4 weeks. On the other hand, with the use 
of SPL, the animals were recurrence-free until the end of the experimental protocol. This was attributed to the antibiotic 
therapy administered at the beginning of the protocol, as this led to a regression of the bacterial pyoderma and involution 
of the lesions. However, after suspending antibiotics, it was observed that, by the end of the study, 83.33% of the dogs 
still had a low level of pruritus, few or no lesions, which were considered acceptable to most owners. At this moment none 
of these patients needed to be subjected to antibiotic treatment. The sums of the scores for the dogs on weeks 1, 12, and 
23 were 53.33, 4.41, and 3.5, respectively, indicating significant improvements of the lesions, showing that the proposed 
protocol with SPL was able to prevent new episodes of pyoderma. 
Keywords: atopic dermatitis, keratinocytes, pyoderma, bacterin.
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INTRODUCTION
CAD is an inflammatory dermatopathy which 
occurs frequently in dogs. The epidermis tends to 
colonize and adhere to staphylococcal bacteria more 
frequently when compared to healthy dogs [7,17,29]. 
An antimicrobial immune response deficit has been 
reported, thus enabling bacterial proliferation [21] and 
recurrent pyoderma [7,22,28,29]. 
Staphylococcal infections correlate with the 
clinical signs of CAD. They play a role in the pathogen-
esis of this dermatopathy by perpetuating the cutaneous 
inflammatory response. The treatment of recurrent 
pyoderma seems to be associated with a partial or 
almost entire reduction of pruritus in this cases [5,26]. 
Acute episodes of bacterial pyoderma can be 
treated with topical or systemic antibiotic therapy [5]; 
however, when the symptoms recur or cannot be treated 
by other means, prophylactic antibiotics may represent 
an effective alternative [22], although this represents a 
risk for the development of a resistant infection [14]. 
The use of bacterins has been previously 
studied, mainly for the control of recurrent idiopathic 
superficial pyoderma [10]. SPL is a bacterin obtained 
from Staphylococcus aureus, which enhances the cel-
lular and humoral responses against staphylococcal [6]. 
The aim of this study was to assess whether the use 
of SPL is effective in the control of recurrent staphy-
lococcal infections in dogs with AD, as a means to 
reduce the frequency of pyoderma episodes, lessen the 
intensity of the lesions and pruritus, and consequently 




A longitudinal, prospective, randomized study 
was conducted with 13 dogs, diagnosed with recur-
rent pyoderma secondary to AD at the Dermatology 
and Allergology Veterinary Service of the Veterinary 
Animal Hospital at PUCPR. The study dogs were all 
over one year of age, of both genders, pure or mixed 
breeds, with atopic dermatitis and a history of recur-
rent bacterial pyoderma, whose pruritus had improved 
by approximately 80% or more after an isolated an-
timicrobial therapeutic protocol, without the use of 
concomitant systemic or topical corticosteroid therapy. 
The average time to recurrence of pyoderma episodes 
was 2-4 weeks, after suspension of antibiotic therapy 
for at least 21 days.
The diagnosis of AD was established by 
observing the presence of intense, chronic, primary 
pruritus responsive to corticosteroids in the distal por-
tions of the limbs, abdomen, axillae, and ears, in which 
the clinical signs did not respond to the exclusion of 
allergens present in the saliva of arthropods or after 
dietary restriction with original protein for 6-10 weeks. 
Culture and antibiotic sensitivity tests
For each dog, the contents of an intact pustule 
was collected with a sterile swab and subsequently 
submitted to microbiological analysis. The samples 
were inoculated in sheep blood agar (5%) and Mac-
Conkey agar and subjected to enzyme tests (catalase, 
coagulase, and oxidase), biochemical tests (mannitol 
fermentation), production of smears to investigate the 
staining characteristics, and isolation of the pathologic 
agent through inoculation in Brain Heart Infusion 
medium for susceptibility testing. After identifying 
the responsible agent, an antibiotic sensitivity test was 
produced to determine the sensitivity profile of the 
isolated agent against the following antimicrobials: 
amoxicillin and clavulanate, cefotaxime, cefovecin, 
clindamycin, marbofloxacin, ciprofloxacin, enrofloxa-
cin, azithromycin, and oxacillin. 
SPL protocol
The protocol was performed with Staphylococ-
cus aureus Phage Lysate Staphage Lysate (SPL®)1. The 
animals included in the study underwent the following 
therapeutic protocol: 1st phase (from week 1 to 12): 
0.5 mL of SPL subcutaneously (SC) twice a week for 
the first 12 weeks; 2nd phase (from week 13 to 16): 1.0 
mL of SPL (SC) once a week for 4 weeks; 3rd phase 
(weeks 18 and 20): 1.0 mL of SPL (SC) once every 15 
days; 4th phase (week 23): 1.0 mL of SPL (SC) after 
a 3-week interval from the last dose on week 20; 5th 
phase (week 26): no application.
Systemic antibiotic therapy was established for 
the first 4-6 weeks of the SPL protocol, based on the 
antibiotic sensitivity tests.
Scores assessments
The animals underwent clinical examina-
tion every week and their owners were questioned 
regarding the pruritus and overall health of the pet. 
Subsequently, they were instructed to check a value 
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in the standardized pruritus score chart described by 
Rybnicek et al. [27]. 
Dermatological lesions (papules, pustules, 
crusts, erythema, and epidermal collarettes) were 
evaluated weekly, and a numerical lesion scale (modi-
fied from Carlotti et al. [3]) was used on weeks 1, 12, 
and 23, based on the dermatological evaluations. The 
total score of each examined week was obtained by 
adding up the individual scores of each lesion in each 
specific location (head, ears, chest, axillae, abdomen, 
perineum, limbs, and paws), ranging from 0-3, with 0 
= no lesion; 1 = a few lesions; 2 = many separate le-
sions; 3 = many confluent lesions.
Statistical analysis
Fisher’s exact test was used to verify the ef-
fectiveness of the treatment. The Kruskal–Wallis test 
was used for the statistical analysis of the nonparamet-
ric data, followed by Dunn’s test for comparisons of 
the means. The significance level was set as 5% (α = 
0.05), with P ≤ 0.05 considered statistically significant. 
All calculations were performed using the Statistical 
Software GraphPad Prism version 3.00 for Windows, 
(San Diego, CA, USA).
RESULTS
A total of 13 dogs with recurrent pyoderma 
secondary to atopic dermatitis were included in the 
experiment. Of these, there were 3 males and 10 
females. The mean age was 5 years, and the breeds 
included were 3 Dachshunds, 2 Golden Retrievers, 2 
Yorkshire terriers, 1 Poodle, 1 Maltese, 1 Lhasa Apso, 
1 Shih Tzu, 1 English Bulldog, and 1 NBD. One dog 
(number 8) left the treatment before the end of proto-
col, all statistic data refers 12 dogs (except culture and 
antibiotic sensitivity tests).  
Among the bacteria isolated from the dogs, 5 of 
13 dogs presented a positive culture for Staphylococcus 
aureus, and 8 of 13 dogs presented a positive culture 
for Staphylococcus pseudintermedius.
About the S. aureus strains, 20% were 
resistant to amoxicillin and clavulanate, 40 % to 
cefovecin, cefotaxime, ciprofloxacin, clindamycin, 
azithromycin, marbofloxacin and oxacillin and 60% 
to enrofloxacin. Two strains (40%) presented multi-
resistant characteristics.    
For S. pseudintermedius strains, 12,5 % were 
resistant to amoxicillin and clavulanate, 20% to 
clindamycin, azithromycin, marbofloxacin and oxa-
cillin, 37,5% to cefovecin, cefotaxime, enrofloxacin 
and ciprofloxacin. Two strains (25%) presented multi-
resistant characteristics.
The individual lesion scores obtained in the 
evaluations from weeks 1, 12, and 23 are shown in 
Graph 1 The sums of the scores for the dogs on weeks 
1, 12, and 23 were 53.33, 4.41, and 3.5, respectively, 
indicating significant improvements of the lesions (P 
< 0.001), as shown in Graph 2.
During the therapeutic protocol with SPL, a 
significant decline in the pruritus was observed in the 
treated dogs (P < 0.05). In week 1, the mean pruritus 
index was 7.33 on the Rybnicek scale [27]; in weeks 
12 and 23, the mean indices were 2.41 and 1.91, re-
spectively, as shown in Graph 3.
Graph 1. Individual lesion scores of the dogs on weeks 1, 12, and 23.
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Graph 2. Summative lesion scores of the dogs on weeks 1, 12, and 23 (Dunn’s test). 
*P < 0.001 compared to the first week.
Graph 3. Individual pruritus scores of the dogs during weeks 1 through 23 (Kruskal-Wallis). 
*P < 0.05 compared to the first week; **P < 0.001 compared to the first week.
DISCUSSION
Fitzgerald [9] reported that S. pseudintermedius 
seem to show specificity for the corneocytes in dogs. In fact, 
several authors have described that this is the most isolated 
agent from the skin of dogs with bacterial pyoderma [1-
4,29]. S. aureus, on the other hand, resides on the skin and 
mucous membranes of humans and has been commonly 
isolated from atopic patients [5,16,19], while its presence 
in dogs has been reported to occur mainly secondary to 
certain risk factors, such as chronic or recurrent infections 
[14,20], as was the case in this study. However, in Brazil, 
Penna et al. [23] isolated S. aureus in only 12.5% of dogs 
with bacterial pyoderma, and in another similar study, the 
species was not isolated in any patient [24].
Resistance to enrofloxacin, a broad-spectrum 
veterinary antibiotic that is considered to be a second-line 
drug, coincides with the data obtained by Prescott et al. 
[25]. According to their study, the increased resistance 
to this and other antimicrobials can be attributed to their 
indiscriminate use in veterinary hospitals and private 
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clinics. Moreover, four dogs from this study (30.77%) 
showed multidrug resistance. According to Fitzgerald 
[9], multidrug resistance can be determined through the 
phenotypic data obtained from the antibiotic sensitivity 
tests, that is, when there is resistance to beta-lactam antibi-
otics along with resistance associated with the other three 
classes of antibiotics. In recent years, this phenomenon 
has been widely discussed and studied, not only due to 
its increasing prevalence in the veterinary field, but also 
due to the emerging growth of infections by multidrug-
resistant strains of S. aureus and S. pseudintermedius [11].
Before treatment with SPL, the selected animals 
presented worsening of the pruritus during the pyoderma 
eczema episodes (pruritic), resulting in the emergence of 
a vicious cycle where the pruritus induced the appear-
ance of new lesions. The improvement of the lesions in 
current study could be clearly correlated with control of 
pruritus. This founds are close to humans, which S. aureus 
colonization has a correlation with the severity of atopic 
dermatitis in chronic lesional patients and the treatment 
with antibiotics has a positive effect. Furthermore, tran-
sepidermal penetration of staphylococcal antigens was well 
demonstrated [5]. Several studies have demonstrated that 
S. aureus isolates from AD patients produce superantigens, 
the majority inducing production of superantigen-specific 
immunoglobulin E [7]. Staphylococcal activity could also 
cause enhance damage to the epidermal barrier. Ceramidase 
from S. aureus can cause hydrolysis of ceramides in atopic 
skin whilst IL-4 from T helper type 2 (TH2) cells has been 
shown to suppress ceramide production in epidermal sheets 
and induce synthesis of fibronectin, an adherence target of 
staphylococci [13].  It was also demonstrated that adherence 
of S. pseudintermedius to the corneocytes of atopic dogs 
is significantly greater than to those of healthy dogs [29]. 
According to Simou et al., atopic dogs with a low degree 
of pruritus are similar to healthy dogs in terms of their 
staphylococcal adherence receptor expression, whereas 
more severe pruritus is associated with upregulation and 
results in an increase in adherence of S. pseudintermedius 
to canine corneocytes. Studies have been suggested that 
staphylococcal components could serve as allergens in 
dogs and stimulate an IgE response against these bacteria. 
Thus, atopic dogs are more likely to suffer flares when 
presented pyoderma [8]. 
The control of pruritus associated with pyo-
derma eczema of the dogs in this study before the vac-
cination protocol with SPL was satisfactory when they 
were subjected to antibiotic therapy; however, after 
suspending therapy, the bacterial infections recurred, on 
average, after 2-4 weeks. On the other hand, with the use 
of SPL, the animals were recurrence-free until the end 
of the experimental protocol. Initially, at the beginning 
of the protocol, the improvement was attributed to the 
antibiotic therapy, as this led to a regression of the bacte-
rial pyoderma and involution of the lesions. However, 
after suspending antibiotics, it was observed that, by 
the end of the study, 83.33% of the dogs still had a low 
level of pruritus, which was considered acceptable to 
most owners. Deboer et al. [5] subjected 13 dogs with 
recurrent idiopathic superficial pyoderma to therapy with 
SPL for 18 weeks and examined the lesions by the end 
of the experiment, after withdrawing treatment, as in this 
study. According to the author, the control of bacterial 
pyoderma was linked to a series of effects of SPL on 
the immune system, including increased cellular and 
humoral immunity, specifically against staphylococcus 
antigens by serum immunoglobulin E and G. In addi-
tion, SPL stimulates immunocompetent cells to produce 
tumor necrosis factor-alpha, interferon-gamma, and in-
terleukin-1 and -2 cytokines, and increases bacterial ad-
hesion, thereby enabling phagocytosis by macrophages 
and neutralization of toxic proteins [10,18], increasing 
the response by T-lymphocyte suppressors, and reducing 
bacterial hypersensitivity [12]. These effects are consis-
tent with the findings regarding pruritus attenuation for 
the animals in this study. It is possible that these effects 
occur due to SPL promoting desensitization to bacterial 
antigens in allergic animals [18]. 
CONCLUSION
The use of SPL was able to significantly mini-
mize pruritus and decrease cutaneous reactivity and the 
rate of recurrent tegumentary staphylococcal infections 
in dogs with atopic dermatitis. Thus, it is appears to be a 
safe and effective option for the control of bacterial pyo-
derma secondary to atopic dermatitis in the long-term. 
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